- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 413/02 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
Patent holdings for IPC class C07D 413/02
Total number of patents in this class: 220
10-year publication summary
7
|
14
|
14
|
15
|
8
|
12
|
10
|
6
|
10
|
3
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Boehringer Ingelheim International GmbH | 4629 |
10 |
Merck Sharp & Dohme Corp. | 2247 |
8 |
Centrexion Therapeutics Corporation | 64 |
7 |
Abbvie Inc. | 1808 |
6 |
Merck Sharp & Dohme LLC | 3689 |
6 |
Bristol-myers Squibb Company | 5080 |
5 |
Genentech, Inc. | 3742 |
5 |
Bayer HealthCare LLC | 1415 |
5 |
Epizyme, Inc. | 383 |
5 |
Merck & Co., Inc. | 607 |
4 |
Syngenta Participations AG | 4970 |
4 |
Samsung Display Co., Ltd. | 30585 |
3 |
MEI Pharma, Inc. | 80 |
3 |
F. Hoffmann-La Roche AG | 7958 |
2 |
Janssen Pharmaceutica N.V. | 3839 |
2 |
Merck Patent GmbH | 5909 |
2 |
Takeda Pharmaceutical Company Limited | 2961 |
2 |
Alexion Pharmaceuticals, Inc. | 606 |
2 |
Alkahest, Inc. | 95 |
2 |
Astex Therapeutics Limited | 267 |
2 |
Other owners | 135 |